Work

Non-clinical evaluation of NT-112, an autologous T cell product engineered to express an HLA-C*08:02-restricted TCR targeting KRAS G12D and resistant to TGF-b inhibition.

Year: 2024

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2024.42.16_suppl.e14533

Authors: Jennifer Ma, Vanessa Tubb, Michelle Mojadidi, Kayla Meade, Xiangjun Kong, Paula Kroon, Aastha Sareen, Bas Stringer, Oscar Krijgsman, Yvonne Claasen, Jules Gadiot, Karen Buchner, Sander Eshuis, Ton Schumacher, Carsten Linneman, Thomas Kuilman, Jeroen van Heijst, Gavin Bendle, Arianne Perez

Institution: Stedelijk Museum Amsterdam

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4399324924

Cites:

Cited by: 4

Related to: 10